Apogee Therapeutics (APGE) Research & Development (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Research & Development data on file, last reported at $60.8 million in Q1 2026.

• Research & Development for Q1 2026 came in at $60.8 million, up 31.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $229.1 million (up 23.5% YoY), and the FY2025 annual result was $214.7 million, up 27.91% from the prior year.
• Research & Development rose to $60.8 million in Q1 2026 per APGE's latest filing, from $58.4 million in the prior quarter.
• Over five years, Research & Development peaked at $60.8 million in Q1 2026 and troughed at $1.4 million in Q2 2022.
• A 5-year average of $33.5 million and a median of $31.1 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2025: Research & Development jumped 863.12% in 2023, then declined 2.96% in 2025.
• A 5-year view of Research & Development shows it stood at $12.2 million in 2022, then jumped by 137.17% to $29.0 million in 2023, then surged by 108.02% to $60.2 million in 2024, then decreased by 2.96% to $58.4 million in 2025, then advanced by 4.06% to $60.8 million in 2026.
• Business Quant data shows APGE's Research & Development at $60.8 million in Q1 2026, $58.4 million in Q4 2025, and $54.2 million in Q3 2025.